Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

Rhea-AI Summary

Relmada Therapeutics (Nasdaq: RLMD) announced it will report Q2 2022 financial results on August 11, 2022, after market close. A conference call and live audio webcast are scheduled for the same day at 4:30 PM ET. The company’s lead product, REL-1017, is in late-stage development for major depressive disorder (MDD) and has shown promising results in a Phase 2 trial, demonstrating rapid and sustained antidepressant effects compared to placebo. The trial also confirmed a favorable safety profile, as previously noted in Phase 1 studies.

Positive

• REL-1017 demonstrated rapid and sustained antidepressant effects in Phase 2 trial.
• The Phase 2 study showed a favorable pharmacokinetic, safety, and tolerability profile consistent with earlier Phase 1 results.

Negative

• None.

CORAL GABLES, Fla., Aug. 5, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter and six months ended June 30, 2022, after the market close on Thursday, August 11, 2022. The company will host a corporate update conference call and live audio webcast at 4:30 PM Eastern Time on Thursday, August 11, 2022.

Live Conference Call & Webcast:
Toll Free:	888-220-8474
International:	856-344-9221
Conference ID:	1883312
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1559727&tp_key=588ed8d666

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of major depressive disorder (MDD). The ongoing Reliance Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid, robust, and sustained antidepressant effects with statistically significant improvements compared to placebo. The Phase 2 study also showed a favorable pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with results observed in previously completed Phase 1 studies.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive and monotherapy treatment for MDD. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact: 
Tim McCarthy
LifeSci Advisors 
212-915-2564 
Tim@LifeSciAdvisors.com

Media Inquiries: 
FischTank PR 
Relmada@FischTankPR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-report-second-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-august-11-2022-301600750.html

SOURCE Relmada Therapeutics, Inc.

FAQ

When will Relmada Therapeutics report its financial results?

Relmada Therapeutics will report its financial results for the second quarter on August 11, 2022.

What are the key features of REL-1017?

REL-1017 is an NMDA receptor channel blocker targeting hyperactive channels, currently in late-stage development for major depressive disorder.

What time is the Relmada Therapeutics conference call scheduled?

The conference call is scheduled for 4:30 PM ET on August 11, 2022.

What were the results of the Phase 2 trial for REL-1017?

The Phase 2 trial for REL-1017 demonstrated rapid, robust, and sustained antidepressant effects with statistically significant improvements compared to placebo.